{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-227940","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2024-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.833972+00:00","generated_at":"2026-05-31T01:16:08.350736+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA lifts clinical hold on Biomea Fusion's BMF-219 for type 2 and type 1 diabetes trials","bullets":["FDA lifted clinical hold on Phase I/II trials COVALENT-111 (type 2 diabetes) and COVALENT-112 (type 1 diabetes) as of Sept 26, 2024.","CEO stated safety signals from Phase 2a Escalation Study did not translate to Phase 2b Expansion Study; no confirmed serious liver injury.","Company expects to announce a third development candidate (oral GLP-1 agonist) in Q4 2024.","Topline Week 26 data from ~200-patient Phase 2b COVALENT-111 and Phase 2a COVALENT-112 (20 patients) expected Q4 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-227940","json":"https://secwatch.observer/filing/0001193125-24-227940.json","markdown":"https://secwatch.observer/filing/0001193125-24-227940.md","text":"https://secwatch.observer/filing/0001193125-24-227940.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524227940/0001193125-24-227940-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312524227940/d310466d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:16:08.350736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}